Chromaderm, Inc.

1 in Phase 3

Quick facts

Phase 3 pipeline

Ruboxistaurin mesylate · Ophthalmology / Endocrinology
Ruboxistaurin mesylate is a protein kinase C (PKC) beta inhibitor that reduces vascular permeability and inflammation in diabetic microvascular complications.

Phase 2 pipeline

LY333531

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors: